{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=raltegravir",
    "query": {
      "intervention": "raltegravir"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 125,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=raltegravir&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T19:56:58.574Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00738569",
      "title": "Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-07",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738569"
    },
    {
      "nct_id": "NCT02218320",
      "title": "Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Colonoscopy with biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-10",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2018-12-26",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218320"
    },
    {
      "nct_id": "NCT00774683",
      "title": "A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "AIDS"
      ],
      "interventions": [
        {
          "name": "Raltegravir (Isentress®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kristine Patterson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2008-08",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2011-10-25",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774683"
    },
    {
      "nct_id": "NCT00594646",
      "title": "HIV Non Occupational Post-Exposure Prophylaxis (PEP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "TRUVADA + Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fenway Community Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2008-02",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594646"
    },
    {
      "nct_id": "NCT00830804",
      "title": "Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir/Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2009-04",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00830804"
    },
    {
      "nct_id": "NCT01330199",
      "title": "Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Females"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic Sampling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 49,
      "start_date": "2012-02",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01330199"
    },
    {
      "nct_id": "NCT01164605",
      "title": "Pilot Study of Raltegravir Lipodystrophy IISP",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California Institute for Research and Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2010-10",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2012-05-18",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164605"
    },
    {
      "nct_id": "NCT00887653",
      "title": "Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "Hyperlipidemia",
        "Hypertriglyceridemia",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Miriam Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-05",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2014-10-10",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Providence, Rhode Island",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00887653"
    },
    {
      "nct_id": "NCT00863668",
      "title": "Raltegravir Activity In Lymphoid Tissues",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Efavirenz + Tenofovir DF/Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir + Tenofovir DF/Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Colonoscopy with biopsies",
          "type": "PROCEDURE"
        },
        {
          "name": "Inguinal Lymph Node Excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-03",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2015-05-18",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00863668"
    },
    {
      "nct_id": "NCT02285114",
      "title": "Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "3rd ARV agent",
          "type": "DRUG"
        },
        {
          "name": "Boosted PIs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-20",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-09-02T19:56:58.574Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285114"
    }
  ]
}